WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018026442) SMALL MOLECULE INHIBITION FOR PREVENTING OR TREATING FIBROTIC DISEASES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/026442    International Application No.:    PCT/US2017/038597
Publication Date: 08.02.2018 International Filing Date: 21.06.2017
IPC:
A61K 31/4184 (2006.01), A61K 31/4745 (2006.01), A61K 31/496 (2006.01)
Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, 12th Floor Oakland, California 94607-5200 (US)
Inventors: CORTOPASSI, Gino; (US).
TOMILOV, Alexey; (US).
TOROK, Natalie; (US).
JIANG, XiaoSong; (US)
Agent: ROBERTS, Byron N.; (US).
HAO, Joe C.; (US).
PRESLEY, Andrew D.; (US)
Priority Data:
62/369,616 01.08.2016 US
Title (EN) SMALL MOLECULE INHIBITION FOR PREVENTING OR TREATING FIBROTIC DISEASES
(FR) INHIBITION DE PETITES MOLÉCULES DANS LA PRÉVENTION OU LE TRAITEMENT DES MALADIES FIBROTIQUES
Abstract: front page image
(EN)The present invention provides methods for preventing or treating a fibrotic disease in a subject. In some embodiments, the fibrotic disease is fatty liver disease, non-alcoholic fatty liver disease, or non-alcoholic steatohepatitis. In particular aspects, the methods comprise administering a small molecule inhibitor of Shc to achieve pharmacological suppression of Shc protein activity in the subject.
(FR)L'invention concerne des méthodes de prévention ou de traitement d'une maladie fibrotique chez un patient. Dans certains modes de réalisation, la maladie fibrotique est la stéatose hépatique, la stéatose hépatique non alcoolique ou la stéatohépatite non alcoolique. Dans des aspects particuliers, les méthodes selon l'invention consistent à administrer un inhibiteur à petites molécules de Shc pour obtenir la suppression pharmacologique de l'activité de la protéine Shc chez le patient.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)